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There are some 38 venomous snake species in South Africa (SA), of 
which approximately half are dangerous to humans.[1] Snake species 
and density vary across the regions of SA.[2] Prevalent species include 
the Mozambique spitting cobra (Naja mossambica) and puff adder 
(Bitis arietans), an elapid and viperid respectively, both of which have 
a potent cytotoxic venom. The black mamba (Dendroaspis polylepis) 
and various cobra (Naja) species are elapids possessing potent 
neurotoxic venom and muscle weakness. Rarely, the boomslang 
(Dispholidus typus), a colubrid with a haemorrhagic venom, can 
cause potentially fatal bleeding.
The severity of a snakebite is highly variable and dependent 
on numerous factors. Snakes will utilise their venom differently 
depending on the situation, controlling the volume injected and the 
fang contact time with their prey.[3] Defence bites that are designed to 
fend off danger may in some cases deliver less or no venom, resulting 
in a dry bite.[3-6] The potency of venom varies with the species of 
snake and in larger snakes the volume of expelled venom is usually 
higher.[3,5] In the case of cytotoxic bites, the severity of injury is 
critically dependent on the body part bitten and the depth at which 
the venom is injected. 
In the absence of objective criteria, the presumed severity of a bite 
is typically dependent on the attending doctor’s own experience and 
clinical judgement. This process of establishing severity is highly 
subjective and is included in guidelines for snakebite management in 
SA.[7] The severity of envenomation may not be initially appreciated 
by admitting doctors. Cytotoxic swelling may progress insidiously, as 
may the effects of systemic toxicity, resulting in shock. In addition, 
coagulopathy may not be identified until the patient manifests with 
lethal haemorrhaging.
Guidelines have been developed to assist doctors to treat patients 
with snakebite. The recommendations on which our own institution’s 
treatment protocol is based were developed in 2005 and are largely 
derived from the knowledge and experience of a single surgeon.[7]
Most guidelines are based on clinical grading systems that rely on 
the clinician’s ability to evaluate the clinical manifestations evident in 
the patient. A number of scoring systems for use in North American 
crotalid bites have been published.[8-11] Coagulopathy is a major feature 
of such bites and these systems typically include coagulation studies. 
Such systems are unlikely to be directly transferable to the bites of 
other snakes with a different toxicity profile. Dart et al.[12] proposed 
a complex guide for crotalid bites in the form of a detailed scoring 
system, the Snakebite Severity Score (SSS). This detailed scoring system 
is limited by a reliance on subjective judgement by the physician, 
the time it takes to do the score in the clinical setting and the fact 
that it was validated retrospectively. Scharman and Noffsinger[13] 
modified the SSS score for copperhead snakebites by excluding the 
coagulation abnormality parameter and adding a progression of 
swelling parameter to produce a score based on clinical assessment 
alone. Gold et al.[5] described three parameters to guide clinicians when 
assessing snakebite in the USA. Two of these parameters are clinical; 
the third parameter is the presence of coagulation abnormalities. Some 
authorities find the published scoring systems to have little value in the 
clinical setting and believe they are of more value in the research setting 
than in clinical practice.[14] 
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delay to admission >7 hours (OR 4.63), white cell count >10 × 109/L (OR 3.15), platelets <92 × 109/L (OR 2.35), haemoglobin <7.1 g/dL 
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predictive value and negative predictive value were 81.8% and 65.2%, respectively.
Conclusion. Our results show that the identified score is a useful adjunct to clinical assessment in managing snakebite. Its value is greatest 
when used in those patients who fall in the mild to moderate clinical category. Until our severity score has been validated (or modified) for 
use across SA, we propose to name it the Zululand Severity Score; a true SA Severity Score may follow.
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That said, the need for an objective and 
reliable scoring system persists. Bites from 
the most venomous SA snakes are often 
severe and may be fatal; there is therefore 
an imperative to identify the more severe 
cases early and to treat them vigorously. On 
the other hand, the mainstay of treatment 
in SA is a polyvalent equine antiserum 
with a venerable ancestry extending back 
to 1928. Initially a bivalent antiserum, it is 
now raised against venom derived from 10 
species. However, its use is associated with 
a high rate of anaphylaxis and it is essential 
that its use is restricted to patients who really 
require it.[15]
We therefore undertook a study to identify 
the factors most strongly predictive of an 
adverse outcome in our population, arising 
from which we propose a scoring system 
called the Zululand Snakebite Score (ZSS) 
that is validated in our setting. We suggest 
that its greatest value is in identifying those 
patients who do not appear overtly seriously 
affected at first presentation, but are at 
high risk of progression to severity over 
the ensuing hours. In such cases intensive 
monitoring and repeated evaluation are 
mandatory, and the early use of antivenom 
may be justified. 
Methods
Setting and participants
The Ngwelezane Hospital serves a popu-
lation of 3 million and is the referral hospital 
for 20 district hospitals in the subtropical 
northeast of SA. This region has a very high 
incidence of snakebite.[15-19] The Emergency 
Department sees approximately 60 000 
new patients annually. In the summer 
months, up to 10% of admissions are due 
to snakebite. All snakebite admissions to 
the Emergency Department from the local 
Uthungulu district and referrals from further 
regions such as the districts of Zululand 
and Umkhanyekhude were included in 
the study. The patient history of a bite 
and the evidence of fang marks confirmed 
the diagnosis of snakebite. Presentations 
ranged from mild (often dry bites) to severe 
limb- or life-threatening envenomation. All 
patients were reviewed by an emergency 
medicine specialist and treated with a 
standard snakebite protocol based on the 
recommendations of Blaylock.[7] All patients 
had baseline blood tests taken on admission 
and received basic treatment that included 
analgesia, fluids and tetanus toxoid. 
Outcomes
The primary outcome was an active treatment 
intervention (ATI), which we defined as the 
administration of antivenom or a surgical 
procedure at any stage during admission. The 
decision to treat a patient with antivenom 
was made by senior emergency medicine 
specialists with extensive experience in 
snakebite. The indications for antivenom 
treatment were: severe cytotoxic swelling, 
active bleeding in the case of haemotoxic 
envenomation, or symptomatic weakness 
in neurotoxic envenomations. The surgical 
procedures were defined as debridement of 
wound necrosis, skin grafts, fasciotomy for 
compartment syndrome or amputations, and 
the decision for this was made by a senior 
surgeon with experience in the management 
of snakebite.
Study design 
We performed a validation study using 
two separate patient cohorts (Fig. 1). The 
development cohort consisted of all patients 
with snakebite who presented to the Ngwe-
lezane Hospital Emergency Department from 
December 2008 to December 2013. Data 
from 983 admissions over this time were 
retrieved and analysed retrospectively. Factors 
predictive of ATI were identified using 
bivariate and multivariable adjusted logistic 
regression. Receiver operating characteristic 
(ROC) curve analysis was performed and the 
optimal cut-off score for predicting an ATI 
identified. These factors were then used to 
develop a standard scoring system. 
The score was then tested prospectively for 
accuracy in a new validation cohort consisting 
of all patients admitted for snakebite during 
the high-incidence season under the same 
criteria from 1 December 2014 to 31 March 
2015. In addition, the optimal cut-off score 
in the validation cohort was also determined 
and compared with the optimal cut-off 
score in the development cohort. All other 
factors were unchanged between the two 
cohorts, including the definitions of ATI, 
the indications for surgery or antivenom, 
treatment protocols and the identities of the 
senior staff supervising therapy. 
Statistical analysis
Data were stored on a protected Excel 
database, version 14.4.7 (Microsoft, USA) 
and were analysed using Stata 13.0, StataCorp 
Development cohort
Retrospective data collection
December 2008 - March 2013
n=983
Validation cohort
Prospective data collection
December 2014 - March 2015
n=100
Patients included
n=879
Patients included
n=100
Predictors of risk for the primary
outcome (ATI) identied and the
optimal cut-o score determined
Validation of risk factors
identied in the development 
cohort and predictive accuracy
assessed
Patients excluded
(missing les)
n=104
Snakebite admissions included over a 
6-year period for all cohorts 
n=1 083
Fig. 1. Patient selection for both development and validation cohorts.
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LP and statistical package 3.0.3 (StataCorp, USA). Associations 
between ATI and categorical predictors were assessed using a Pearson 
χ2 or Fisher’s exact test. Differences in means of continuous variables 
were tested using a Student’s t-test. For non-parametric data the 
Wilcoxon rank-sum test was used. A p-value of <0.05 was considered 
significant. Factors predictive of ATI were identified using bivariate 
and multivariate analysis and cut-off points determined by ROC 
curve analysis.
The study was approved by the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (ref. no.: BE034/14).
Results
We recorded 983 admissions for snakebite over the period December 
2008 to December 2013. Of these, 104 were excluded as the clinical 
records were incomplete; 879 patients were therefore entered into the 
development cohort. Prospective data for 100 admissions over the period 
from 1 December 2014 to 31 March 2015 (the snakebite high-incidence 
season) were used for the validation cohort (the round number of 100 
is coincidental). Demographic and laboratory data for both cohorts are 
presented in Table 1. Of note were significant differences in age, white 
cell count (WCC) and INR between the two cohorts.
Development cohort 
Of 879 snakebite admissions, 146 reached the primary endpoint of 
an ATI. Antivenom alone was administered to 64 patients, 49 of 
879 patients received a surgical intervention without antivenom 
and 33 patients received both. Table 2 shows the ATI risk predictors 
derived from multivariate analysis. Individually no parameter was 
strongly predictive for ATI. We therefore combined them using 
a scoring system in which a positive criterion attracted a score of 
1. Further testing revealed that weighting the individual criterion 
according to the number (%) of cases or the odds ratios (ORs) and 
using the coefficients derived from the logistic regression did not 
provide a significantly more accurate prediction than the use of the 
crude score of 1 each. Therefore, in order to promote ease of use, we 
settled on a standard score of 1 per positive criterion, to produce a 
severity score which we named the Zululand Snakebite Score (ZSS) 
on a six-point scale (Table 3). ROC curve analysis (Fig. 2A) on the 
minimum number of ATI parameters, returned a value of 4 as the 
optimal cut-off number for predicting an ATI (area under the curve 
(AUC) 0.804; 95% confidence interval (CI) 0.758 - 0.84). 
Validation cohort
Of 100 patients, 40 reached the primary outcome of an ATI. 
Antivenom alone was administered to 19 patients, 4 patients 
underwent a surgical intervention without antivenom and 17 patients 
received both. Within the validation cohort 37 of 100 patients had 
one or more risk parameters. Applying the ZSS to this cohort, ROC 
curve analysis (Fig. 2B) confirmed a minimum cut-off score of 4 as 
the optimal value for predicting an ATI (AUC 0.807; 95% CI 0.728 - 
0.886). The accuracy of the ZSS in predicting progression to an ATI 
is reported in Table 4.
Table 1. Demographic and laboratory data
Characteristic
Development
cohort
Validation
cohort p-value
Age (years), mean (SD) 21.7 (15.0) 15.7 (13.6) <0.001
Children (<12 years), n (%) 222 (25.3)  57 (57.0) <0.001
Sex
Female 431 (49.1) 42 (42.0) 0.179
Male 447 (50.9) 58 (58.0)
Elapsed time between bite and admission (hours), mean (SD) 9.5 (17.4) 10.4 (9.6) 0.614
Elapsed time between bite and admission, n (%)
<6 hours 438 (59.0) 47 (47.0) 0.023
≥6 hours 305 (41.0) 53 (53.0)
Urea (mmol/L), mean (IQR) 3.4 (2.6 - 4.2) 3.7 (2.8 - 4.3) 0.216
Creatinine (mmol/L), mean (IQR) 63 (47 - 78) 57 (36 - 88) 0.605
WCC (× 109/L), mean (IQR) 9 (6.8 - 12.0) 12.6 (9.0 - 17.0) <0.001
Platelets (× 109/L), mean (IQR) 248.5 (196 - 320) 271 (204 - 368) 0.113
INR, mean (IQR) 1.08 (1.01 - 1.18) 1.20 (1.10 - 1.40) <0.001
Estimation of severity by admitting doctor
Severe 146 (16.6) 26 (26.0) 0.019
Not severe 733 (83.4) 74 (74.0)
SD = standard deviation; IQR = interquartile range.
Table 2. ATI risk predictors derived from multivariate analysis
Calculated ATI risk predictor
and optimal value AUC OR (95% CI) p-value
ATI cases in which criterion is 
positive (%)
Age <14 yr 0.657 2.13 (1.27 - 3.57) 0.004 57
Duration to admission >7 h 0.718 4.63 (2.71 - 7.89) <0.001 53
WCC >10 × 109/L 0.690  3.15 (1.88 - 5.26) 0.023 69
INR >1.2 0.758 2.25 (1.12 - 4.53) <0.001 17
Platelets <92 × 109/L 0.508  2.35 (1.01 - 5.49) 0.048 11
Haemoglobin <7.1 g/dL 0.685  5.68 (2.14 -15.00) <0.001 3
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Discussion
Snakebite patients that are obviously severe cases, such as those who 
present in systemic shock, have active bleeding, manifest neurotoxic 
muscle weakness or have gross cytotoxic swelling, are easily identified 
by the admitting doctor, and the decision to prescribe antivenom 
early or plan for surgery is clinically intuitive. However, it is within 
the mild to moderate envenomation group that a portion of patients 
will progress to a severe clinical outcome requiring an ATI. The 
decision to prescribe antivenom appropriately in these patients is 
difficult. The risk of anaphylaxis using the South African Institute 
of Medical Research (SAIMR) polyvalent antivenom in our region 
is significant; studies report rates of between 25% and 73%.[16,18-20] 
Bearing this in mind, doctors must weigh the benefits of antivenom 
against the risks of anaphylaxis.
Ours is the first attempt to objectively grade snakebites in SA. 
Our scoring system aims to predict which patients will require more 
aggressive treatment. The ATI group is intuitively those patients who 
have had a more severe clinical course, and ATI could possibly act as 
a surrogate marker for severity. The difficulty in grading the severity 
of the patient by judging the swelling post envenomation is evident 
when, in our experience, there is no consistency among doctors 
who treat snakebites. In our validation cohort 14 of 40 patients who 
received an ATI were initially assessed as not severe. This supports 
the view that there is a group of patients that are clinically assessed as 
non-severe yet progress over time to a more severe course and require 
an ATI such as antivenom or some form of surgery. 
Identifying simple demographic parameters, such as age <14 years, 
delay to admission and noting abnormal admission blood results 
such as the INR, haemoglobin, WCC and platelets, the doctor can 
rapidly score a patient and predict whether they will require ATI. 
In Fig. 3 we propose a new guideline that incorporates both the ZSS 
and a clinical assessment that is dynamic.[14] The ZSS component will 
support the doctor’s initial clinical assessment in those cases where 
classifying patients is challenging. Clinicians who score snakebite 
patients as 4 or more can be reasonably confident that the patient 
will suffer a more severe clinical course, and will most likely require 
ATI. If a patient has a positive score, there is an 82% probability 
that they will progress to an ATI, based on the positive predictive 
value (PPV) of the validation cohort. This will alert the doctor to 
the patient’s potential severity and support the decision to prescribe 
early antivenom. In the case of cytotoxic envenomation, the damage 
done to tissues can be profound and is not reversible. Thus, there 
is less damage done to the subcutaneous tissues when a decision to 
administer antivenom is made early. In many cases this may reduce or 
prevent surgery of the damaged limb. These results support the ZSS 
as a ‘rule-in’ tool for patients who require an ATI.
The lower negative predictive value (NPV) of the ZSS cannot safely 
rule out those patients with a score of <4 as likely to have a non-severe 
uneventful course. This is a limitation that should be borne in mind 
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Fig. 2. ROC curve analysis of optimal breakpoint for a crude score of >4 as a 
predictor for ATI. (A) Development cohort (N=879). (B) Validation cohort 
(N=100).
Table 4. The accuracy of the ZSS in predicting progression to 
an ATI
Development cohort, % 
(95% CI)
Validation cohort, % 
(95% CI)
Sensitivity 17.8 (10.9 - 26.7) 22.5 (10.1 - 38.5)
Specificity 98.7 (97.3 - 99.5) 96.6 (88.5 - 99.6)
PPV 75.0 (57.8 - 83.4) 81.8 (54.4 - 91.0)
NPV 84.9 (76.1 - 93.9) 65.2 (44.0 - 94.0)
Table 3. Six-point scale Zululand Snakebite Score 
ATI risk predictors Allocated score
Children <14 yr 1
Duration >7 h 1
WCC >10 × 109/L 1
INR >1.2 1
Platelets <92 × 109/L 1
Haemoglobin <7.4 g/dL 1
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when using the ZSS, and a period of observation is advocated in 
these patients. Although the patient with a score below 4 has a 65% 
probability of not progressing to an ATI, 35% will actually do so. It 
is essential that clinicians understand that patients who have a low 
score should undergo a period of at least 24 hours of observation and 
monitoring before being discharged. 
The risk predictors we identified for ATI, and indirectly severity, 
are in keeping with reports from other countries. Although the 
snake species from Asia and the Americas differ from the SA 
species, there do appear to be some consistent parameters that 
allude to severity. Age, coagulation abnormalities, low haemoglobin, 
leukocytosis, thrombocytopenia and delays to treatment are all 
correlated with adverse outcomes in the Asian and North American 
viper species. [8,11,12,21,22] It is notable that acute kidney injury is a 
significant factor in Indian snakebites, while we found no correlation 
with severity and in our setting acute kidney injury is seldom 
reported.[16,18,19] One study from southern India reported acute kidney 
injury in 28% of snakebite patients, with a significant association with 
mortality.[23]
Study limitations
We acknowledge the difficulty of clearly defining true severity and the 
influence that clinical judgement and experience have in influencing 
a doctor’s decision to proceed to an ATI. We believe that the species 
of snake inflicting the bite may in itself be a potent predictor of 
the likelihood of a severe outcome. Identification of the species 
by detecting specific venom antigens might substantially improve 
prognostication, but these tests are currently not available in SA.
Our sample did not include patients who were treated in other 
hospitals in the region or patients who were exclusively treated 
by traditional healers in our local area. We acknowledge that the 
severity score will have to be validated for use in other areas of 
southern Africa with a different spectrum of snake species, and may 
require modification. Until our severity score has been validated (or 
modified) by other investigators in different settings across SA, we 
propose to keep its name as the Zululand Severity Score (ZSS); a true 
SA Severity Score may follow.
Conclusions
Current guidelines such as those proposed by Blaylock and the 
Federation of Infectious Diseases of South Africa (FIDSSA) essen-
tially leave the classification of what constitutes a severe snakebite 
up to the clinician’s clinical judgement.[7,24] This research attempts 
to objectively quantify severe snakebite presentations utilising tested 
parameters in a scoring system. We hope that such a scoring system 
will assist doctors who manage snakebite envenomation.
SYSTEMIC SHOCK
• Central or peripheral circulatory collapse
• Hypotension with peripheral shutdown
• Drowsiness, confusion
• Depressed level of consciousness
HAEMOTOXIC
• Active internal bleeding (any site)
• Extensive petechiae
• Conjunctival haemorrhage
• Diuse ecchymosis
• Ongoing bleeding from puncture
  sites/fang marks
EXTENT or SITE
• Extensive limb swelling
• Whole forearm and/or upper arm
• Whole lower leg and/or thigh
• Whole hand or foot
LOCAL EFFECTS
• Bullae and/or necrosis 
  beyond bite site
• Documented 
  compartment syndrome
CYTOTOXIC
ANTIVENOM
INTENSIVE MONITORING AND SUPPORT
CONSULT SURGEON IN CYTOTOXIC ENVENOMATION
Discharge home if
patient stable
Ward observation
12 -24 hDevelopment of any 'severe' category signs
or
Signicant swelling progression >2.5 cm/h
High care
Monitoring and
supportive therapy
Moderate signs of tissue damage
Swelling beyond bite site
(less extensive than 'severe' category)
Necrosis at bite site only
Local bruising or erythema
Minor local signs at bite site
Fang mark bleeding
Poorly dened weakness
No symptoms
SEVERE CLINICAL
FEATURES
PATIENT PRESENTATION
(fang marks evident)
NON–SEVERE
CLINICAL FEATURES
Baseline blood tests
(FBC, INR, WBCT)
SCORE ≥4 APPLY ZSS SCORE <4
NEUROTOXIC
• Muscle weakness/paralysis
• Ptosis of eyelids
• Hypersalivation
• Swallowing diculties
• Muscle fasciculations
• Circumoral paraesthesia
• Respiratory paralysis
Fig. 3. Proposed guideline for managing snakebites in KwaZulu-Natal. (WBCT = whole blood clotting time; no clotting after 20 min = haemotoxicity (severe 
category).)
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